RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its sequencing by extension technology, with initial presented data on speed and accuracy that are comparable or better than NovaSeq X from Illumina. The firm noted that the competitive offering from Roche creates more uncertainty for Illumina.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target lowered to $90 from $110 at BofA
- Illumina Faces Potential Downside: Sell Rating and Cautious Outlook Amidst Market Challenges
- Icahn boosts CVR Partners, cuts Illumina in Q4
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Sell Rating for Illumina Amid Backlog Concerns and Market Challenges